Ivor Percent

2.8k citations
33 papers · 715 · 1 hit paper · h-index 13

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • Lung Cancer Research Studies
    • Cancer Genomics and Diagnostics

Papers in

    • Cancer Immunotherapy and Biomarkers 12
    • Colorectal Cancer Treatments and Studies 4
    • Cancer Treatment and Pharmacology 4
    • Renal cell carcinoma treatment 7
    • Prostate Cancer Treatment and Research 6
    • Lung Cancer Treatments and Mutations 5

Ivor Percent

33 papers receiving 699 citations

Hit Papers

Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC). 2022 · 125 citations
1250+1+2Years since publication4080120

Peers

Ivor Percent
Comparison fields: 5 of 50
  • Oncology 412
  • Cancer Research 155
  • Pulmonary and Respiratory Medicine 299
  • Molecular Biology 371
  • Immunology 78
Replace Hirva Mamdani with:
Hirva Mamdani United States
Marie‐Paule Sablin France
Toshiki Takemoto Japan
Bethany Pitcher Canada
Aimee Bence Lin United States
Karen A. Cadoo United States
Yasir Y. Elamin United States
Kiyoko Kuwata Japan
Shinnosuke Ikemura Japan
Max Hallin United States
Ivor Percent relative to Hirva Mamdani United States Hirva Mamdani's profile →
Citations per field
00.5×1.5×2.2×
Hirva Mamdani · 1×
Citations per year

Countries citing papers authored by Ivor Percent

Since Specialization
Citations

This map shows the geographic impact of Ivor Percent's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ivor Percent with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ivor Percent more than expected).

Fields of papers citing papers by Ivor Percent

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ivor Percent. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ivor Percent. The network helps show where Ivor Percent may publish in the future.

Co-authors

The 25 scholars most cited alongside Ivor Percent, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ivor Percent Line = papers co-authored together Ivor Percent links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase 1/2 study of ARV-110, an androgen receptor (AR) PROTAC degrader, in metastatic castration-resistant prostate cancer (mCRPC).
Hit paper breakdown →
2022125
2 2010116
3 202285
4 201966
5 201840
6 202231
7 202131
8 201029
9 201927
10 200825
11 201922
12 200520
13 202113
14 202012
15 202011
16 20199
17 20088
18 20246
19 20215
20 20234

About Ivor Percent

Ivor Percent is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Epidemiology, having authored 33 papers that have together received 715 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (12 papers), Cancer Genomics and Diagnostics (8 papers), Renal cell carcinoma treatment (7 papers), Prostate Cancer Treatment and Research (6 papers), Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (4 papers), Breast Cancer Treatment Studies (4 papers) and Cancer Treatment and Pharmacology (4 papers). The work is most often cited by research in Oncology (412 citations), Cancer Research (155 citations), Pulmonary and Respiratory Medicine (299 citations), Molecular Biology (371 citations) and Immunology (78 citations). Ivor Percent has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Arash Rezazadeh Kalebasty, Andres Forero‐Torres, James Posey, Tina E. Wood, Slawomir Wojtowicz‐Praga, Mansoor N. Saleh, Jatin J. Shah, Catherine Copigneaux, Feng Luo and Thomas E. Hutson. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Biotherapy and Radiopharmaceuticals, Cancer Research and Cancer.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact